1
|
Rajsic S, Breitkopf R, Rugg C, Bukumiric Z, Reitbauer J, Treml B. Thrombotic Events Develop in 1 Out of 5 Patients Receiving ECMO Support: An 11-Year Referral Centre Experience. J Clin Med 2023; 12:jcm12031082. [PMID: 36769730 PMCID: PMC9917555 DOI: 10.3390/jcm12031082] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 01/18/2023] [Accepted: 01/28/2023] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND The use of extracorporeal membrane oxygenation (ECMO) for critically ill patients is growing rapidly given recent developments in technology. However, adverse events are frequently reported that have potentially devastating impacts on patient outcomes. The information on predictors and risk factors for thrombotic events, especially that focusing on the comparison of veno-arterial and veno-venous ECMO configurations, are still inconsistent and sparse; therefore, we aimed to close this gap. METHODS We performed a retrospective analysis of all patients on extracorporeal life support admitted to the intensive care units of a tertiary university center in Europe. RESULTS From 645 patients, 417 who received extracorporeal life support due to cardiogenic shock (290, 70%), respiratory failure (116, 28%) or hypothermia (11, 3%) were included. In total, 22% (92) of the patients experienced thrombotic events with a similar incidence in both ECMO configurations. Anticoagulation consisted of unfractionated heparin (296, 71%) and argatroban (70, 17%). Univariate Cox analyses identified hemoconcentration and increased maximal clot firmness (thromboelastometry) as risk factors for thrombosis. Moreover, the patients experiencing thrombosis had longer ECMO duration and intensive care stays. CONCLUSIONS ECMO is a specialized life-support modality with a high risk of complications. A longer ECMO duration is associated with thrombosis occurrence in patients receiving ECMO support. Following hemorrhage, thromboembolic complications are common adverse events. However, in contrast to major bleeding, no impact on mortality was observed. The question arises if a protocol with less anticoagulation may have a role to play in the future.
Collapse
Affiliation(s)
- Sasa Rajsic
- Department of Anesthesia and Intensive Care Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria
| | - Robert Breitkopf
- Department of Anesthesia and Intensive Care Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria
| | - Christopher Rugg
- Department of Anesthesia and Intensive Care Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria
| | - Zoran Bukumiric
- Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Jakob Reitbauer
- Department of Anesthesia and Intensive Care Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria
| | - Benedikt Treml
- Department of Anesthesia and Intensive Care Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria
- Correspondence: ; Tel.: +43-50504-82231
| |
Collapse
|
2
|
Chenevier-Gobeaux C, Ducastel M, Meritet JF, Ballaa Y, Chapuis N, Pene F, Carlier N, Roche N, Szwebel TA, Terrier B, Borderie D. Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients. J Clin Med 2022; 11:jcm11195560. [PMID: 36233427 PMCID: PMC9572304 DOI: 10.3390/jcm11195560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Revised: 09/14/2022] [Accepted: 09/19/2022] [Indexed: 11/24/2022] Open
Abstract
(1) Background: Endocan is a marker of endothelial dysfunction that may be associated with thrombotic events. The aim of the study was to investigate the performance of endocan as a marker of thrombotic events in COVID-19 patients. (2) Methods: We measured endocan in plasma from 79 documented COVID-19 patients classified according to disease severity (from mild to critical). Thrombotic events were recorded. (3) Results: Endocan concentrations at admission were significantly increased according to COVID-19 severity. Levels of endocan were significantly increased in patients experiencing thrombotic events in comparison with those without (16.2 (5.5−26.7) vs. 1.81 (0.71−10.5) ng/mL, p < 0.001). However, endocan concentrations were not different between pulmonary embolism and other thrombotic events. The Receiver Operating Characteristic (ROC) analysis for the identification of thrombotic events showed an area under the ROC curve (AUC) of 0.776 with an optimal threshold at 2.83 ng/mL (93.8% sensitivity and 54.7% specificity). When combining an endocan measurement with D-dimers, the AUC increased to 0.853. When considering both biomarkers, the Kaplan−Meier survival curves showed that the combination of endocan and D-dimers better discriminated patients with thrombotic events than those without. The combination of D-dimers and endocan was independently associated with thrombotic events. (4) Conclusions: Endocan might be a useful and informative biomarker to better identify thrombotic events in COVID-19 patients.
Collapse
Affiliation(s)
- Camille Chenevier-Gobeaux
- Department of Automated Biological Diagnostic, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
- Correspondence:
| | - Morgane Ducastel
- Department of Automated Biological Diagnostic, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
| | - Jean-François Meritet
- Department of Virology, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
| | - Yassine Ballaa
- Department of Automated Biological Diagnostic, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
| | - Nicolas Chapuis
- Department of Haematology, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
| | - Frédéric Pene
- Medical Intensive Care Unit, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
- UMR 8104, INSERM U1016, CNRS, Université de Paris, 75014 Paris, France
| | - Nicolas Carlier
- Department of Pulmonology, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
| | - Nicolas Roche
- Department of Pulmonology, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
- UMR 1016, Institut Cochin, Université de Paris, 75014 Paris, France
| | - Tali-Anne Szwebel
- Department of Internal Medicine, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
- Centre de Référence Maladies Auto-Immunes et Maladies Systémiques Rares, d’Ile-de-France, Université de Paris, 75014 Paris, France
- INSERM U970, Paris–Cardiovascular Research Center (PARCC), Université de Paris, 75015 Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
- Centre de Référence Maladies Auto-Immunes et Maladies Systémiques Rares, d’Ile-de-France, Université de Paris, 75014 Paris, France
- INSERM U970, Paris–Cardiovascular Research Center (PARCC), Université de Paris, 75015 Paris, France
| | - Didier Borderie
- Department of Automated Biological Diagnostic, Cochin Hospital, APHP-Centre Université de Paris, CEDEX 14, 75679 Paris, France
- INSERM UMRs 1124, Université de Paris, 75006 Paris, France
| |
Collapse
|
3
|
Clark CC, Jukema BN, Barendrecht AD, Spanjaard JS, Jorritsma NKN, Smits S, de Maat S, Seinen CW, Verhoef S, Parr NMJ, Sebastian SAE, Koekman AC, van Wesel ACW, van Goor HMR, Spijkerman R, Bongers SH, van der Vries E, Nierkens S, Boes M, Koenderman L, Kaasjager KAH, Maas C. Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity. Front Med (Lausanne) 2021; 8:650129. [PMID: 33968958 PMCID: PMC8100661 DOI: 10.3389/fmed.2021.650129] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 03/25/2021] [Indexed: 12/13/2022] Open
Abstract
Background: Coronavirus disease of 2019 (COVID-19) is associated with a prothrombotic state and a high incidence of thrombotic event(s) (TE). Objectives: To study platelet reactivity in hospitalized COVID-19 patients and determine a possible association with the clinical outcomes thrombosis and all-cause mortality. Methods: Seventy nine hospitalized COVID-19 patients were enrolled in this retrospective cohort study and provided blood samples in which platelet reactivity in response to stimulation with ADP and TRAP-6 was determined using flow cytometry. Clinical outcomes included thrombotic events, and all-cause mortality. Results: The incidence of TE in this study was 28% and all-cause mortality 16%. Patients that developed a TE were younger than patients that did not develop a TE [median age of 55 vs. 70 years; adjusted odds ratio (AOR) = 0.96 per 1 year of age, 95% confidence interval (CI) 0.92-1.00; p = 0.041]. Furthermore, patients using preexisting thromboprophylaxis were less likely to develop a thrombotic complication than patients that were not (18 vs. 54%; AOR = 0.19, 95% CI 0.04-0.84; p = 0.029). Conversely, having asthma strongly increased the risk on TE development (AOR = 6.2, 95% CI 1.15-33.7; p = 0.034). No significant differences in baseline P-selectin expression or platelet reactivity were observed between the COVID-19 positive patients (n = 79) and COVID-19 negative hospitalized control patients (n = 21), nor between COVID-19 positive survivors or non-survivors. However, patients showed decreased platelet reactivity in response to TRAP-6 following TE development. Conclusion: We observed an association between the use of preexisting thromboprophylaxis and a decreased risk of TE during COVID-19. This suggests that these therapies are beneficial for coping with COVID-19 associated hypercoagulability. This highlights the importance of patient therapy adherence. We observed lowered platelet reactivity after the development of TE, which might be attributed to platelet desensitization during thromboinflammation.
Collapse
Affiliation(s)
- Chantal C. Clark
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Bernard N. Jukema
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Arjan D. Barendrecht
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Judith S. Spanjaard
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Nikita K. N. Jorritsma
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Simone Smits
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Steven de Maat
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Cor W. Seinen
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Sandra Verhoef
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Naomi M. J. Parr
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Silvie A. E. Sebastian
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Arnold C. Koekman
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Annet C. W. van Wesel
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Harriet M. R. van Goor
- Department of Internal Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Roy Spijkerman
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
- Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Suzanne H. Bongers
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
- Department of Trauma Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Erhard van der Vries
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Stefan Nierkens
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Marianne Boes
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Leo Koenderman
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
- Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Karin A. H. Kaasjager
- Department of Internal Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Coen Maas
- Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| |
Collapse
|
4
|
Zirngibl F, Flemmig C, Lang P, Künkele A, Eggert A, Schulte JH, Deubzer HE. Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma. Children (Basel) 2020; 7:E198. [PMID: 33126407 DOI: 10.3390/children7110198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 10/13/2020] [Accepted: 10/14/2020] [Indexed: 11/17/2022]
Abstract
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) to treat high-risk neuroblastoma, who developed hepatic sinusoidal obstruction syndrome (SOS) within 48 h after systemic TA treatment for a hemodynamically relevant hemorrhage. Defibrotide treatment resolved hepatic SOS, but the short time between TA administration and SOS onset suggests a causal association.
Collapse
|
5
|
Abstract
RATIONALE Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disease. Patients with PNH often experience a high incidence (14%-40%) of thrombotic events, which are mainly venous and rarely arterial thrombotic events. Because it is very rare, delay in diagnosis is common in patients with PNH, imposing a remarkable impact on patient's management and prognosis. PATIENT CONCERNS We presented a 33-year-old female case with no medical history of any systemic illnesses who complained of approximately 1-month progressively worsening constant heartburn, and was also hospitalized twice due to acute myocardial infarction (AMI). DIAGNOSES In our case, AMI occurred twice, whereas there were no cardiovascular risk factors and abnormalities based on the angiography of the coronary artery. Flow cytometry analysis showed that 25% of CD55 and CD59 were lost on the surface of neutrophils, and 30% of CD55 and CD59 were lost on the surface of the blood cells. Thus, our diagnosis of this patient was AMI secondary to PNH. INTERVENTIONS AND OUTCOMES For the first myocardial infarction, local hospitals used thrombolytic therapy to alleviate symptoms. After the patient's second myocardial infarction was treated in our hospital, we adopted coronary interventional therapy. Considering the patient's situation, eculizumab was given for treatment. The patient was gradually restored to achieve stability, and the follow-up observation showed that there was no arterial thrombosis. LESSONS This case report aimed to provide a reliable reference for the rare cause of AMI. In addition, PNH should be highly taken into consideration in young patients who have a rare cause of AMI.
Collapse
Affiliation(s)
- Gang Li
- Cardiology Division in Geriatric Institute, Hebei General Hospital, Shijiazhuang
| | - Rui Hu
- General Clinical Laboratory, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Yifang Gao
- Cardiology Division in Geriatric Institute, Hebei General Hospital, Shijiazhuang
| |
Collapse
|
6
|
Ponce AT, Hong KL. A Mini-Review: Clinical Development and Potential of Aptamers for Thrombotic Events Treatment and Monitoring. Biomedicines 2019; 7:biomedicines7030055. [PMID: 31357413 PMCID: PMC6784064 DOI: 10.3390/biomedicines7030055] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2019] [Revised: 07/21/2019] [Accepted: 07/24/2019] [Indexed: 01/01/2023] Open
Abstract
The unique opportunity for aptamer uses in thrombotic events has sparked a considerable amount of research in the area. The short half-lives of unmodified aptamers in vivo remain one of the major challenges in therapeutic aptamers. Much of the incremental successful therapeutic aptamer stories were due to modifications in the aptamer bases. This mini-review briefly summarizes the successes and challenges in the clinical development of aptamers for thrombotic events, and highlights some of the most recent developments in using aptamers for anticoagulation monitoring.
Collapse
Affiliation(s)
- Alex T Ponce
- Department of Pharmaceutical Sciences, Nesbitt School of Pharmacy, Wilkes University, 84 W. South Street, Wilkes-Barre, PA 18766, USA
| | - Ka Lok Hong
- Department of Pharmaceutical Sciences, Nesbitt School of Pharmacy, Wilkes University, 84 W. South Street, Wilkes-Barre, PA 18766, USA.
| |
Collapse
|
7
|
Alirezaei T, Hajimoradi B. Is thrombotic event a side effect of oral buprenorphine abuse? Two case reports. Clin Case Rep 2019; 7:740-743. [PMID: 30997076 PMCID: PMC6452464 DOI: 10.1002/ccr3.2086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Revised: 12/01/2018] [Accepted: 02/02/2019] [Indexed: 12/02/2022] Open
Abstract
Buprenorphine is used to treat opioid addiction. The spectrum of complications of oral buprenorphine is not well known. We describe two cases and based on a hypothesis is proposed which suggests that the use of oral buprenorphine could be relevant to the increase of thrombotic risk.
Collapse
Affiliation(s)
- Toktam Alirezaei
- Cardiology Department of Shohaday‐e‐Tajrish HospitalShahid Beheshti University of Medical Sciences (SBMU)TehranIran
| | - Behzad Hajimoradi
- Cardiology Department of Shohaday‐e‐Tajrish HospitalShahid Beheshti University of Medical Sciences (SBMU)TehranIran
| |
Collapse
|